Use of Home Sleep Apnea Testing to Mitigate the Effects of COVID-19: Modification of the Phase I Magnap Clinical Trial Protocol

First-in-human evaluation of a novel magnetic apnea prevention (Magnap) device for obstructive sleep apnea (OSA) treatment was disrupted by the COVID-19 pandemic which negatively impacted the ability to track patient outcomes with in-lab polysomnograms (PSG). The objective of this study is to report the modifications undertaken in response to COVID-19 and to discuss the feasibility of home sleep apnea testing (HSAT) to monitor novel OSA therapies.